<DOC>
	<DOCNO>NCT02344563</DOCNO>
	<brief_summary>A randomized , single-dose , two-way crossover study evaluate bioequivalence two formulation meropenem ( meropenem intravenous injection 0.5 g ) intravenous infusion healthy volunteer .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Meropenem Intravenous Injection</brief_title>
	<detailed_description />
	<mesh_term>Meropenem</mesh_term>
	<criteria>Healthy adult male female subject 2045 year age . Body weight within 80120 % ideal body weight high equal 50 kg male subject 45 kg female subject . Ideal body weight ( kg ) = [ height ( cm ) 80 ] × 0.7 male subject Ideal body weight ( kg ) = [ height ( cm ) 70 ] × 0.6 female subject Acceptable medical history physical examination include : particular clinically significant abnormality Xray ECG result within six month prior study . particular clinical significance general disease history within two month prior study . Acceptable vital sign ( within normal limit consider investigator physician clinical significance ) screening , include pulse rate , blood pressure body temperature . Acceptable clinical chemistry determination ( within normal limit consider investigator physician clinical significance ) within two month prior study , include AST ( SGOT ) , ALT ( SGPT ) , γGT , alkaline phosphatase , total bilirubin , albumin , glucose , BUN , uric acid , creatinine , total cholesterol triglyceride ( TG ) . Acceptable hematology ( within normal range consider investigator physician clinical significance ) within two month prior study , include hemoglobin , hematocrit , red blood cell count , white blood cell count differential platelet . Acceptable urinalysis ( within normal limit consider investigator physician clinical significance ) within two month prior study , include pH , blood , glucose , ketone , bilirubin protein . Female subject childbearing potential practicing acceptable method birth control least seven day prior study end study judge investigator ( ) surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy perform subject ) . Have sign write informed consent participate study . A clinically significant disorder involve cardiovascular , respiratory , hepatic , renal , gastrointestinal , immunologic , hematologic , endocrine neurologic system ( ) psychiatric disease ( determined clinical investigator ) . A clinically significant illness surgery within four week prior study ( determined investigator ) . History gastrointestinal obstruction , inflammatory bowel disease , gallbladder disease , pancreas disorder last two year history gastrointestinal tract surgery last five year . History kidney disease urination problem last two year deem investigator clinically significant . Known suspected history drug abuse within lifetime judge investigator . History alcohol addiction abuse within last five year judge investigator . Have personal history family history drug allergy . Subjects demonstrate positive meropenem skin test screen prior study . Evidence chronic acute infectious disease . Female subject demonstrate positive urine pregnancy screen prior study . Female subject currently breastfeed . Taking drug know induce inhibit hepatic drug metabolism within four week prior study . Examples inducer include : piperidines , carbamazepine , dexamethasone rifampin . Examples inhibitor include : cimetidine , diphenhydramine , fluvastatin , methadone ranitidine . Taking prescription medication within four week nonprescription medication ( exclude flu vaccination ) within two week prior study . Use investigational drug within four week prior study . Donating 250 mL blood within two month prior study donate plasma ( e.g . plasmapheresis ) within two week prior study . Any medical reason determine clinical investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>volunteer</keyword>
</DOC>